BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 16034146)

  • 21. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.
    Long HM; Leese AM; Chagoury OL; Connerty SR; Quarcoopome J; Quinn LL; Shannon-Lowe C; Rickinson AB
    J Immunol; 2011 Jul; 187(1):92-101. PubMed ID: 21622860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection.
    Alter G; Hatzakis G; Tsoukas CM; Pelley K; Rouleau D; LeBlanc R; Baril JG; Dion H; Lefebvre E; Thomas R; Côté P; Lapointe N; Routy JP; Sékaly RP; Conway B; Bernard NF
    J Immunol; 2003 Jul; 171(1):477-88. PubMed ID: 12817033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART.
    Romiti ML; Cancrini C; Castelli-Gattinara G; Di Cesare S; Ciaffi P; Bernardi S; De Gasperi MR; Halapi E; Rossi P
    AIDS; 2001 Nov; 15(16):2075-84. PubMed ID: 11684926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
    Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.
    Casazza JP; Betts MR; Picker LJ; Koup RA
    J Virol; 2001 Jul; 75(14):6508-16. PubMed ID: 11413318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma.
    van Baarle D; Hovenkamp E; Callan MF; Wolthers KC; Kostense S; Tan LC; Niesters HG; Osterhaus AD; McMichael AJ; van Oers MH; Miedema F
    Blood; 2001 Jul; 98(1):146-55. PubMed ID: 11418474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia.
    Rallón N; Sempere-Ortells JM; Soriano V; Benito JM
    J Antimicrob Chemother; 2013 Nov; 68(11):2616-25. PubMed ID: 23833186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
    Blake N; Haigh T; Shaka'a G; Croom-Carter D; Rickinson A
    J Immunol; 2000 Dec; 165(12):7078-87. PubMed ID: 11120837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.
    Wilkinson J; Cope A; Gill J; Bourboulia D; Hayes P; Imami N; Kubo T; Marcelin A; Calvez V; Weiss R; Gazzard B; Boshoff C; Gotch F
    J Virol; 2002 Mar; 76(6):2634-40. PubMed ID: 11861829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
    Beran O; Holub M; Spála J; Kalanin J; Stanková M
    Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
    Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
    Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
    J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.
    Bourboulia D; Aldam D; Lagos D; Allen E; Williams I; Cornforth D; Copas A; Boshoff C
    AIDS; 2004 Feb; 18(3):485-93. PubMed ID: 15090801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
    Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
    J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
    Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
    J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.
    Catalina MD; Sullivan JL; Bak KR; Luzuriaga K
    J Immunol; 2001 Oct; 167(8):4450-7. PubMed ID: 11591771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.
    Guadalupe M; Reay E; Sankaran S; Prindiville T; Flamm J; McNeil A; Dandekar S
    J Virol; 2003 Nov; 77(21):11708-17. PubMed ID: 14557656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.